From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024 ...

Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...

BMY is looking to turn its business around, banking on the strong uptake of new drugs. The recent spate of positive ...

Ameritas Advisory Services LLC increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 9.4% in ...

Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...

The drug comes from Bristol Myers Squibb's whopping $14 billion acquisition of biotech company Karuna Therapeutics at the end of 2023. But the drug's roots are in treating Alzheimer's.

The acquisition added Mirati’s lung cancer ... best-in-class actinium-based radiopharmaceutical therapeutics, to Bristol Myers’ oncology portfolio. Earlier, the Committee for Medicinal ...

Bristol Myers Squibb Co. closed 1.88% below its 52-week high of $61.10, which the company reached on January 27th.

(Bloomberg) -- Bristol Myers Squibb Co. said its new schizophrenia ... was a key piece of Bristol’s acquisition of Karuna. US regulators approved Cobenfy in September, becoming the first new ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on BMY stock, giving a Buy rating on January 12.Invest with ...